Molecular Price To Sales Ratio from 2010 to 2024
| MOLN Stock | USD 5.42 0.22 4.23% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 16.36380574 | Current Value 18.48 | Quarterly Volatility 15.58889384 |
Check Molecular Partners financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Molecular Partners' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2 M, Interest Expense of 46.5 K or Selling General Administrative of 12.2 M, as well as many indicators such as Price To Sales Ratio of 18.48, Dividend Yield of 0.0 or PTB Ratio of 0.62. Molecular financial statements analysis is a perfect complement when working with Molecular Partners Valuation or Volatility modules.
Molecular | Price To Sales Ratio |
Latest Molecular Partners' Price To Sales Ratio Growth Pattern
Below is the plot of the Price To Sales Ratio of Molecular Partners AG over the last few years. Price to Sales Ratio is figured by comparing Molecular Partners stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Molecular Partners sales, a figure that is much harder to manipulate than other Molecular Partners AG multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Molecular Partners' Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Molecular Partners' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 33.39 X | 10 Years Trend |
|
Price To Sales Ratio |
| Timeline |
Molecular Price To Sales Ratio Regression Statistics
| Arithmetic Mean | 20.27 | |
| Geometric Mean | 14.97 | |
| Coefficient Of Variation | 76.89 | |
| Mean Deviation | 11.12 | |
| Median | 16.36 | |
| Standard Deviation | 15.59 | |
| Sample Variance | 243.01 | |
| Range | 57.0715 | |
| R-Value | 0.38 | |
| Mean Square Error | 223.01 | |
| R-Squared | 0.15 | |
| Significance | 0.16 | |
| Slope | 1.34 | |
| Total Sum of Squares | 3,402 |
Molecular Price To Sales Ratio History
About Molecular Partners Financial Statements
Molecular Partners investors utilize fundamental indicators, such as Price To Sales Ratio, to predict how Molecular Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 16.36 | 18.48 |
Pair Trading with Molecular Partners
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Molecular Partners position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will appreciate offsetting losses from the drop in the long position's value.Moving against Molecular Stock
| 0.42 | GOSS | Gossamer Bio | PairCorr |
| 0.37 | VRDN | Viridian Therapeutics | PairCorr |
| 0.37 | TERN | Terns Pharmaceuticals | PairCorr |
| 0.35 | NTRB | Nutriband | PairCorr |
The ability to find closely correlated positions to Molecular Partners could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Molecular Partners when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Molecular Partners - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Molecular Partners AG to buy it.
The correlation of Molecular Partners is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Molecular Partners moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Molecular Partners moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Molecular Partners can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Molecular Partners Correlation against competitors. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.14) | Revenue Per Share 0.182 | Quarterly Revenue Growth (0.73) | Return On Assets (0.21) | Return On Equity (0.37) |
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.